FDA has approved Lipfendra, developed by American pharmaceutical company Merck, for adults with high LDL cholesterol. It ...
Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as ...
The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, for the treatment of high cholesterol. Two medical experts ...
Zacks Investment Research on MSN
MRK stock jumps on FDA nod for cholesterol-lowering pill
Shares of Merck MRK rose more than 3% on Thursday after the company announced that the FDA approved enlicitide as the first ...
A significant breakthrough in heart disease prevention arrived on July 16, 2026, with the FDA approval of Lipfendra ...
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them ...
Enlicitide receives FDA approval as the first oral PCSK9 inhibitor, offering a new approach to lowering cholesterol in adults ...
South Carolina’s In Our DNA SC program brings free genomic screening to all 46 counties, uncovering hidden cancer and heart ...
A new daily pill will give people with stubbornly high cholesterol a cheaper, needle-free way to lower their levels.
The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Merck & Co Inc.’s MRK LIPFENDRA (enlicitide) as an adjunct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results